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Acinetobacter baumannii is undoubtedly one of the most successful pathogens
responsible for hospital-acquired nosocomial infections in themodern healthcare system.
Due to the prevalence of infections and outbreaks caused by multi-drug resistant
A. baumannii, few antibiotics are effective for treating infections caused by this
pathogen. To overcome this problem, knowledge of the pathogenesis and antibiotic
resistance mechanisms of A. baumannii is important. In this review, we summarize
current studies on the virulence factors that contribute to A. baumannii pathogenesis,
including porins, capsular polysaccharides, lipopolysaccharides, phospholipases, outer
membrane vesicles, metal acquisition systems, and protein secretion systems.
Mechanisms of antibiotic resistance of this organism, including acquirement of
β-lactamases, up-regulation of multidrug efflux pumps, modification of aminoglycosides,
permeability defects, and alteration of target sites, are also discussed. Lastly, novel
prospective treatment options for infections caused by multi-drug resistant A. baumannii
are summarized.
Keywords: antimicrobial resistance, Acinetobacter baumannii, treatment option, resistancemechanism, virulence
factor
INTRODUCTION
Acinetobacter spp. are glucose-non-fermentative, non-motile, non-fastidious, catalase-positive,
oxidative-negative, aerobic Gram-negative coccobacilli (Lin and Lan, 2014). Due to clusters of
closely related species, it is difficult to distinguish Acinetobacter taxonomy using phenotypic
traits and chemotaxonomic methods. Because antibiotic susceptibility and clinical relevance are
significantly different between different genomic species, exact identification of Acinetobacter
species are required (Bergogne-Berezin and Towner, 1996; Dijkshoorn et al., 1996; Houang
et al., 2003; Lee et al., 2007). Many genomic fingerprinting methods have been developed,
including repetitive extragenic palindromic sequence-based polymerase chain reaction (rep-PCR),
pulsed-field gel electrophoresis (PFGE), matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry, ribotyping, amplified ribosomal DNA restriction analysis,
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random amplified polymorphic DNA analysis, multilocus
sequence typing (MLST), RNA spacer fingerprinting, amplified
fragment length polymorphism analysis, and sequence analysis
of 16S-23S rRNA intergene spacer regions or the rpoB and gyrB
genes (Koeleman et al., 1998; Chang et al., 2005; La Scola et al.,
2006; Croxatto et al., 2012; Higgins et al., 2012; Lee C. R. et al.,
2015; Li X. M. et al., 2016).
Among Acinetobacter species, Acinetobacter baumannii is
the most important member associated with hospital-acquired
infections worldwide (Lin and Lan, 2014). This aerobic Gram-
negative coccobacillus had been regarded as a low-grade
pathogen, but it is a successful pathogen responsible for
opportunistic infections of the skin, bloodstream, urinary tract,
and other soft tissues (Peleg et al., 2008). Because many
A. baumannii infections have suddenly been reported among
veterans and soldiers who served in Iraq and Afghanistan
(Centers for Disease and Prevention, 2004), A. baumannii
is referred to as “Iraqibacter.” Multidrug-resistant (MDR) A.
baumannii has spread to civilian hospitals in part by cross-
infection of injured military patients repatriated from war zones
(Peleg et al., 2008). Most A. baumannii infections occur in
critically ill patients in the intensive care unit (ICU) setting
(Fournier and Richet, 2006) and account for up to 20% of
infections in ICUs worldwide (Vincent et al., 2009). Furthermore,
FIGURE 1 | Biology of Acinetobacter baumannii. Studies of virulence factors, pathogenesis, antimicrobial resistance, treatment options of A. baumannii will
provide an important aid for discovering new antibiotics and determining efficient combination therapy, which are essential strategies for combating multidrug-resistant
A. baumannii infections.
the frequency of community-acquired A. baumannii infections
has been increasing gradually (Lin and Lan, 2014). Several
virulence factors have been identified by genomic and phenotypic
analyses, including outer membrane porins, phospholipases,
proteases, lipopolysaccharides (LPS), capsular polysaccharides,
protein secretion systems, and iron-chelating systems (Antunes
et al., 2011; McConnell et al., 2013; Lin and Lan, 2014).
Many reports have shown that A. baumannii rapidly
develops resistance to antimicrobials, and multidrug-resistant
strains have been isolated (McConnell et al., 2013). The
WHO declared that A. baumannii is one of the most serious
ESKAPE organisms (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas
aeruginosa, and Enterobacter species) that effectively escape
the effects of antibacterial drugs (Boucher et al., 2009).
A number of A. baumannii resistance mechanisms are
known, including enzymatic degradation of drugs, target
modifications, multidrug eﬄux pumps, and permeability
defects (Gordon and Wareham, 2010; Kim et al., 2012; Lin
and Lan, 2014). In this review, we summarize the virulence
factors of A. baumannii, antibiotic resistance mechanisms, and
the therapeutic options available for treating A. baumannii
infections. Figure 1 depicts all the features described in this
review.
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Although recent genomic and phenotypic analyses of
A. baumannii have identified several virulence factors
responsible for its pathogenicity, relatively few virulence
factors have been identified in A. baumannii, compared to those
in other Gram-negative pathogens (McConnell et al., 2013). The
proposed A. baumannii virulence factors are summarized in
Table 1.
Porins
Porins are outer membrane proteins associated with modulating
cellular permeability. OmpA is a β-barrel porin and one of the
most abundant porins in the outer membrane. In A. baumannii,
OmpA is the very well-characterized virulence factor with a
variety of interesting biological properties identified in in vitro
model systems (Smith et al., 2007; McConnell et al., 2013). A
randommutagenesis screen showed that theA. baumannii ompA
mutant is defective in inducing apoptosis in human epithelial
cells (Choi et al., 2005). Purified OmpA binds host epithelial
cells, targets mitochondria, and induces apoptosis by releasing
proapoptotic molecules, such as cytochrome c and apoptosis-
inducing factor (Choi et al., 2005; Lee et al., 2010). Another
study showed that OmpA translocates to the nucleus by a novel
monopartite nuclear localization signal and induces cell death
(Choi et al., 2008a). OmpA also plays a major role in adherence
and invasion of epithelial cells by interacting with fibronectin
(Choi et al., 2008b; Gaddy et al., 2009; Smani et al., 2012), and
binds to factor H in human serum (Kim et al., 2009), which may
allow A. baumannii to avoid complement-mediated killing. The
TABLE 1 | Identified virulence factors of Acinetobacter baumannii.
Virulence factor Proposed role in pathogenesis References
Porin (OmpA, Omp33-36, Omp22, CarO,
OprD-like)
Adherence and invasion, induction of apoptosis, serum resistance,
biofilm formation, persistence
Choi et al., 2005, 2008b; Gaddy et al., 2009; Kim
et al., 2009; Lee et al., 2010; Fernandez-Cuenca
et al., 2011; Smani et al., 2012, 2013; Rumbo et al.,
2014; Wang et al., 2014; Huang et al., 2016
Capsular polysaccharide Growth in serum, survival in tissue infection, biofilm formation Russo et al., 2010; Iwashkiw et al., 2012;
Lees-Miller et al., 2013
Lipopolysaccharide (LPS) Serum resistance, survival in tissue infection, evasion of the host
immune response
Luke et al., 2010; Lin et al., 2012; McQueary et al.,
2012; McConnell et al., 2013
Phospholipase (PLC and PLD) Serum resistance, invasion, in vivo survival Camarena et al., 2010; Jacobs et al., 2010; Stahl
et al., 2015; Fiester et al., 2016
Outer membrane vesicle (OMV) Delivery of virulence factors, horizontal transfer of antibiotic
resistance gene
Kwon et al., 2009; Jin et al., 2011; Rumbo et al.,
2011; Moon et al., 2012; Jun et al., 2013; Li Z. T.
et al., 2015
Iron acquisition system (acinetobactin and
NfuA)
In vivo survival, persistence, killing of host cells Gaddy et al., 2012; Penwell et al., 2012; Zimbler
et al., 2012; Fiester et al., 2016; Megeed et al., 2016
Zinc acquisition system (ZnuABC and ZigA) In vivo survival Hood et al., 2012; Nairn et al., 2016
Manganese acquisition system (MumC and
MumT)
In vivo survival Juttukonda et al., 2016
Type II protein secretion system In vivo survival Johnson et al., 2015; Elhosseiny et al., 2016;
Harding et al., 2016
Type VI protein secretion system Killing of competing bacteria, host colonization Carruthers et al., 2013; Wright et al., 2014; Jones
et al., 2015; Repizo et al., 2015; Ruiz et al., 2015
Type V protein secretion system Biofilm formation, adherence Bentancor et al., 2012b
Penicillin-binding protein 7/8 and β-lactamase
PER-1
Serum resistance, in vivo survival, adherence Sechi et al., 2004; Russo et al., 2009
CipA Serum resistance, invasion Koenigs et al., 2016
Tuf Serum resistance Koenigs et al., 2015
RecA In vivo survival Aranda et al., 2011
SurA1 Serum resistance, in vivo survival Liu D. et al., 2016
GigABCD In vivo survival, killing of host cells Gebhardt et al., 2015
UspA In vivo survival, killing of host cells Elhosseiny et al., 2015; Gebhardt et al., 2015
GacS and PaaE Neutrophil influx Cerqueira et al., 2014; Gebhardt et al., 2015;
Bhuiyan et al., 2016
Pili Adherence, biofilm formation Tomaras et al., 2003, 2008
OmpR/EnvZ Killing of host cells Tipton and Rather, 2016
FhaBC Adherence, killing of host cells Perez et al., 2016
AbeD Killing of host cells Srinivasan et al., 2015
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ompA gene is necessary for persistence of A. baumannii in the
mouse lung (Wang et al., 2014).
Furthermore, OmpA is also involved in antimicrobial
resistance of A. baumannii (Sugawara and Nikaido, 2012;
Smani et al., 2014). The major A. baumannii porin is OmpA,
which has 70-fold lower pore-forming activity than that of
OmpF (Sugawara and Nikaido, 2012). Furthermore, disrupting
the ompA gene significantly decreases the minimal inhibitory
concentrations (MICs) of several antibiotics (chloramphenicol,
aztreonam, and nalidixic acid), suggesting that OmpA
participates in the extrusion of antibiotics from the periplasmic
space through the outer membrane and couples with inner
membrane eﬄux systems (Smani et al., 2014). OmpA enhances
survival and persistence of A. baumannii by facilitating
surface motility and biofilm formation (Gaddy et al., 2009;
Clemmer et al., 2011; McConnell et al., 2013). OmpA also
regulates biogenesis of outer membrane vesicles (Moon et al.,
2012). These results suggest that the OmpA protein is an
attractive target for developing novel antibiotics and prevention
strategies. Two recent reports based on immuno-proteomics
and reverse vaccinology suggested that OmpA is a potential
vaccine candidate against A. baumannii (Fajardo Bonin et al.,
2014; Hassan et al., 2016). Actually, the OmpA protein is
immunogenic in healthy individuals and patients with A.
baumannii invasive infections (Zhang et al., 2016). In a mouse
model of A. baumannii infection, mice immunized with
OmpA had a significantly higher survival rate than that of
control mice (Luo et al., 2012; Lin L. et al., 2013; Zhang et al.,
2016).
The 33- to 36-kDa Omp protein (Omp33-36), which acts
as a water passage channel, is another outer membrane porin
associated with A. baumannii cytotoxicity (Smani et al., 2013;
Rumbo et al., 2014). The omp33-36 deletion strain significantly
reduces adherence and invasion of human lung epithelial cells
and cytotoxicity to these cells (Smani et al., 2013). Deletion
of the omp33-36 gene in a murine sepsis model attenuates
lethality and reduces bacterial concentrations in the spleen and
lungs (Smani et al., 2013). One study showed that purified
Omp33-36 induces apoptosis in several different cell types,
including immune and connective tissue cells, by activating
caspases and modulating autophagy (Rumbo et al., 2014).
Omp33-36 is also involved in antibiotic resistance. A. baumannii
strain JC10/01 resistant to carbapenem antibiotics (imipenem
and meropenem) exhibits loss of Omp33-36 and episomal
expression of Omp33-36 in this strain clearly reduces the
MICs of imipenem and meropenem (del Mar Tomas et al.,
2005).
Omp22 has also been identified as a novel, conserved,
and safe antigen for developing effective vaccines to control
A. baumannii infections (Huang et al., 2016), although the
contribution of Omp22 to A. baumannii pathogenicity has
not been determined. Both active and passive immunizations
with Omp22 increase the survival rates of mice, suppress
bacterial burdens in the organs and peripheral blood, and
reduce serum levels of inflammatory cytokines and chemokines
(Huang et al., 2016). Other porins, such as carbapenem-
associated outer membrane protein (CarO) and OprD-like,
are also virulence-related factors associated with attenuated




Beyond OmpA, the A. baumannii envelope is associated
with many factors that contribute to pathogenicity. Among
these, capsular exopolysaccharides and LPS are A. baumannii
pathogenicity factors. Notably, many isolates from patients with
A. baumannii infections express surface capsular polysaccharides
and contain a conserved gene cluster, called the K locus,
which may determine production of capsular polysaccharides
(Koeleman et al., 2001; Hu et al., 2013; Kenyon and Hall, 2013;
Geisinger and Isberg, 2015). A random transposon screening to
identify genes essential for growth in an inflammatory exudative
fluid lead to the identification of the ptk and epsA genes,
which are predicted to be required for capsule polymerization
and assembly (Russo et al., 2010). The ptk and epsA mutants
are deficient in capsule production and have a growth defect
in human serum, resulting in a highly significant decrease
in survival in soft tissue infection sites (Russo et al., 2010).
Mutation in the pglC or pglL gene, which is responsible for
synthesis of the O-pentasaccharide found on glycoproteins
and capsular polysaccharides, also attenuate lethality in a
mouse septicemia model and form abnormal biofilm structures
(Iwashkiw et al., 2012; Lees-Miller et al., 2013). Therefore,
capsular polysaccharides have been proposed to be a target for
protective antibody-based interventions (passive immunization;
Russo et al., 2013).
One study showed that capsular polysaccharides are involved
in antimicrobial resistance of A. baumannii (Geisinger and
Isberg, 2015). Mutants deficient in capsular polysaccharides have
lower intrinsic resistance to peptide antibiotics. In addition,
the presence of antibiotics induces hyperproduction of capsular
polysaccharides (Geisinger and Isberg, 2015). Antibiotic-induced
production of capsular polysaccharides increases resistance to
killing by host complement and increases virulence in a mouse
model of systemic infection (Geisinger and Isberg, 2015). That
study also demonstrated that increased capsule production after
exposure to an antibiotic depends on transcriptional increases in
K locus gene expression, and that expression of K locus genes
is regulated by the bfmRS two-component regulatory system
(Geisinger and Isberg, 2015). bfmR is a gene essential for growth
in human ascites, which is an ex vivo medium that reflects the
infection environment (Umland et al., 2012), and is important
for persistence in the lung in a murine pneumonia model (Wang
et al., 2014). BfmS is also a virulence factor that plays an
important role in biofilm formation, adherence to eukaryotic
cells, and resistance to human serum (Liou et al., 2014).
On report showed BfmR-mediated resistance to complement-
mediated bactericidal activity and resistance to the clinically
important antimicrobials (meropenem and colistin; Russo et al.,
2016). However, that study suggested that BfmR effects are
independent of capsular polysaccharide production. Therefore,
the relationship between BfmRS and capsular polysaccharides
must be described in more detail.
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LPS is the major component of the outer leaflet of the
outer membrane in most Gram-negative bacteria and is an
immunoreactive molecule that induces release of tumor necrosis
factor and interleukin 8 frommacrophages in a Toll-like receptor
4 (TLR4)-dependent manner (Erridge et al., 2007). LPS is
composed of an endotoxic lipid A moiety, an oligosaccharide
core, and a repetitive O-antigen (Lee et al., 2013b). In
A. baumannii, LPS plays a major role in virulence and survival of
A. baumannii (Luke et al., 2010; Lin et al., 2012; McQueary et al.,
2012). Mutant cell lacking LpsB glycotransferase have a highly
truncated LPS glycoform containing only two carbohydrate
residues bound to lipid A, resulting in decreased resistance to
human serum and decreased survival in a rat model of soft tissue
infection (Luke et al., 2010; McConnell et al., 2013). Inhibiting
LpxC, an enzyme involved in the lipid A biosynthesis, dose not
inhibit growth of the bacterium, but suppresses A. baumannii
LPS-mediated activation of TLR4 (Lin et al., 2012). Inhibition
of LpxC in mouse model enhances clearance of A. baumannii
by enhancing opsonophagocytic killing and reduces serum LPS
concentration and inflammation, which completely protectsmice
from lethal infection (Lin et al., 2012; Lee et al., 2013b). These
results indicate that blocking LPS synthesis is a powerful strategy
for discovering novel antibiotics. Modification of LPS contributes
to resistance to antimicrobials. Many studies have shown that
modifications in LPS decrease the susceptibility of A. baumannii
to many clinical important antibiotics, such as colistin (Moffatt
et al., 2010; Arroyo et al., 2011; Beceiro et al., 2011; Pelletier et al.,
2013; Boll et al., 2015; Chin et al., 2015).
Phospholipase
Phospholipase is a lipolytic enzyme essential for phospholipid
metabolism and is a virulence factor in many bacteria, such
as P. aeruginosa, Legionella monocytogenes, and Clostridium
perfringens (Camarena et al., 2010; Flores-Diaz et al., 2016).
Three classes of phospholipases, such as phospholipase A (PLA),
phospholipase C (PLC), and phospholipase D (PLD) have
been defined based on the cleavage site. PLA hydrolyzes fatty
acids from the glycerol backbone, whereas PLC cleaves the
phosphorylated head group from the phospholipid. PLD is
a transphosphatidylase that only cleaves off the head group.
Degradation of phospholipids affects the stability of host cell
membranes, and the cleaved head group can interfere with
cellular signaling, resulting in changes in the host immune
response (Songer, 1997; Flores-Diaz et al., 2016). PLC and
PLD have been identified as virulence factors in A. baumannii
(Camarena et al., 2010; Jacobs et al., 2010; Stahl et al., 2015).
Acinetobacter baumannii ATCC17978 has two PLCs (A1S_0043
and A1S_2055) and inactivation of the A1S_0043 gene leads to
a modest reduction in the cytotoxic effect of A. baumannii on
epithelial cells compared to that of the parental strain (Camarena
et al., 2010; Fiester et al., 2016). Disrupting one (A1S_2989) of the
two PLD genes present in A. baumannii strain 98-37-09 results
in reduced resistance to human serum, decreased capacity for
invading epithelial cells, and decreased virulence in a murine
model of pneumonia (Jacobs et al., 2010). Another report showed
that A. baumannii ATCC 19606 has three PLD genes and all
three play important roles in virulence and host cell invasion
in a concerted manner (Stahl et al., 2015). These results suggest
that phospholipase enzymes are important virulence factors in A.
baumannii pathogenesis.
Outer Membrane Vesicles (OMVs)
OMVs are spherical, 20–200 nm diameter vesicles secreted
by the outer membranes of various Gram-negative pathogenic
bacteria (Kulp and Kuehn, 2010). They are composed of LPS,
outer membrane and periplasmic proteins, phospholipids, and
DNA or RNA, and are recognized as delivery vehicles for
bacterial effectors to host cells (Ellis and Kuehn, 2010). OMVs
deliver diverse virulence factors to the interior of host cells
simultaneously and allow the pathogens to interact with the host
without close contact between bacteria and host cells (Jun et al.,
2013). Many A. baumannii strains secrete OMVs containing
various virulence factors, including OmpA (Kwon et al., 2009;
Jin et al., 2011; Moon et al., 2012), proteases (Kwon et al., 2009),
and phospholipases (Kwon et al., 2009). OMVs derived from A.
baumannii interact with host cells and deliver bacterial effectors
to host cells via lipid rafts, resulting in cytotoxicity (Jin et al.,
2011). Purified OMVs of A. baumannii ATCC 19606 induce
expression of pro-inflammatory cytokine genes in epithelial cells
in a dose-dependent manner (Jun et al., 2013). Notably, OMVs
treated with proteinase do not induce a significant increase in
the expression of pro-inflammatory cytokine genes, suggesting
that themembrane proteins in OMVs are responsible for eliciting
a potent innate immune response (Jun et al., 2013). One study
supports the role of OMVs in A. baumannii pathogenesis. An
A. baumannii strain that produces abundant OMVs with more
virulence factors induces a stronger innate immune response and
is more cytotoxic compared with those of a strain producing
fewer OMVs (Li Z. T. et al., 2015).
Due to the importance of OMVs in A. baumannii virulence,
several reports have shown that A. baumannii OMVs could
be used as an acellular vaccine to elevate protective immunity
(McConnell et al., 2011; Huang et al., 2014). In a mouse model of
disseminated sepsis, vaccination with A. baumanniiATCC 19606
strain OMVs protects mice from challenge with homologous
bacteria and provides protection against other clinical isolates
(McConnell et al., 2011). Similar results were obtained in a
pneumonia mouse model. Bacterial burden, inflammatory cell
infiltration, and inflammatory cytokine accumulation in the
pneumonia model were significantly suppressed by both active
and passive immunization with OMVs (Huang et al., 2014).
These results indicate thatA. baumanniiOMVs can be used as an
acellular vaccine to effectively control A. baumannii infections.
Interestingly, A. baumannii OMVs are also related with the
spread of antibiotic resistance and induce the horizontal transfer
of the OXA-24 carbapenemase gene (Rumbo et al., 2011).
Metal Acquisition System
Although iron is one of the most abundant elements in
environmental and biological systems, ferric iron is relatively
unavailable to bacteria in the preferred state, because of its poor
solubility (10−17 M solubility limit for ferric iron) under aerobic
and neutral pH conditions as well as due to chelation by low-
molecular-weight compounds, such as heme, or high-affinity
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iron-binding compounds, such as lactoferrin and transferrin
(Rakin et al., 2012; Saha et al., 2013). To overcome this iron
limitation, most aerobic bacteria produce a high-affinity iron
chelator known as a siderophore (Saha et al., 2013). Siderophores
are low molecular weight compounds (400–1,000 kDa) with high
affinity for iron. The range of Fe3+-siderophore association
constants is 1012–1052 (Saha et al., 2013). Siderophores have
been classified into catecholates, hydroxymates, and a mixed
type based on the moiety that donates oxygen ligands to
coordinate Fe3+ (Saha et al., 2013). Acinetobacter baumannii also
has iron siderophores and acinetobactin, the best-characterized
A. baumannii siderophore, is a mixed type siderophore with
an oxazoline ring derived from threonine (McConnell et al.,
2013). Acinetobactin is an A. baumannii virulence factor (Gaddy
et al., 2012; Penwell et al., 2012; Megeed et al., 2016). Impaired
acinetobactin biosynthesis and transport functions significantly
reduce the ability of A. baumannii ATCC 19606 cells to persist
within epithelial cells and cause cell damage and animal death
(Gaddy et al., 2012). Mutation in the entA gene, which is
essential for biosynthesis of the acinetobactin precursor 2,3-
dihydroxybenzoic acid, also significantly reduces the capacity of
A. baumannii ATCC 19606 cells to persist within human alveolar
epithelial cells and diminishes the ability to infect and killGalleria
mellonella larvae (Penwell et al., 2012). One study showed that
acinetobactin production occurs significantly more frequently
in MDR A. baumannii isolates than that in avirulent isolates
(Megeed et al., 2016).
The A. baumannii NfuA Fe-S scaffold protein, that
participates in the formation of Fe-S clusters and plays a
role in cell responses to iron chelation and oxidative stress, has
also been identified as a virulence factor (Zimbler et al., 2012).
The nfuA mutant is more sensitive to reactive oxygen species
(ROS), such as hydrogen peroxide and cumene hydroperoxide,
and shows significantly reduced growth in human epithelial
cells. In addition, a G. mellonella infection model showed that
more than 50% of injected G. mellonella larvae die 6 days after
infection with the parental strain, whereas less than 30% of
the larvae die when infected with the nfuA mutant (Zimbler
et al., 2012). One report showed that iron starvation increases
production of PLCs, which increase hemolytic activity of A.
baumannii (Fiester et al., 2016). These reports indicate that
iron acquisition functions play a critical role in A. baumannii
virulence.
The innate immune metal-chelating protein calprotectin
inhibits bacterial growth by host-mediated chelation of metals,
such as zinc (Zn2+ and Zn) and manganese (Mn2+ and Mn)
(Corbin et al., 2008). However, A. baumannii can cause disease
in the presence of this nutritional immune protein in vivo
(Juttukonda et al., 2016). To combat the zinc limitation, A.
baumannii uses a zinc acquisition system (ZnuABC), which is
up-regulated under Zn-limiting conditions, and the znuBmutant
strain experiences Zn starvation at higher Zn concentrations
than that of the wild-type (Hood et al., 2012). ZnuB contributes
to the pathogenesis of A. baumannii pulmonary infections.
Notably, a zinc limitation reduces the imipenem MIC of MDR
A. baumannii to below the clinical breakpoint for imipenem
resistance in A. baumannii (Hood et al., 2012), possibly because
many carbapenemases are metalloenzymes that require Zn for
their hydrolyzing activity. Besides the ZnuABC system, the
novel Zn metallochaperone ZigA has been characterized in A.
baumannii (Nairn et al., 2016). ZigA tightly interacts with Zn,
which is required for bacterial growth under Zn starvation
conditions and for disseminated infection in mice (Nairn et al.,
2016).
The mechanism employed by A. baumannii to overcome
a Mn limitation has been identified. Calprotectin induces Mn
starvation in A. baumannii, which increases transcription of an
NRAMP (Natural Resistance-Associated Macrophage Proteins)
family Mn transporter and a urea carboxylase to resist the
antimicrobial activities of calprotectin (Juttukonda et al., 2016).
A urea carboxylase enzyme (MumC) is important for growth
of A. baumannii in the presence of calprotectin and an
NRAMP family transporter (MumT) contributes to the fitness
of A. baumannii in a murine pneumonia model (Juttukonda
et al., 2016), suggesting that the two proteins are virulence
factors. Acinetobacter baumannii can utilize urea as a sole
nitrogen source, and this urea utilization is required for MumC
(Juttukonda et al., 2016). Based on the contribution of MumC
to A. baumannii resistance to calprotectin, the authors suggest a
connection between metal starvation and metabolic stress, such
as nitrogen starvation.
Protein Secretion Systems
Several protein secretion systems have been identified in A.
baumannii (Weber et al., 2015a). The most recently described A.
baumannii secretion system is a type II secretion system (T2SS)
(Johnson et al., 2015). The T2SS is a multi-protein complex
that is structurally very similar to type IV pili systems, which
is an appendage that is commonly found in Gram-negative
bacteria (Korotkov et al., 2012). T2SS translocates a wide range
of proteins from the periplasmic space to the extracellular
milieu out of the cell or the outer membrane surface. The
T2SS is composed of 12–15 proteins comprised of four sub-
assemblies: a pseudopilus, a cytoplasmic secretion ATPase, an
inner-membrane platform assembly, and a dodecameric outer-
membrane complex (Korotkov et al., 2012; Harding et al., 2016).
Secretion by T2SS is a two-step process. The target proteins
are first translocated to the periplasm by the general secretory
(Sec) system or the twin arginine transport (Tat) system, where
the target proteins are then secreted out of the cell through
the T2SS (Korotkov et al., 2012). Deleting A. baumannii genes
for the T2SS components, gspD or gspE, results in loss of LipA
secretion, indicating that LipA is a T2SS substrate (Johnson et al.,
2015). Because LipA is a lipase that breaks down long-chain
fatty acids, lipA, gspD, and gspE mutant strains are incapable of
growing on long-chain fatty acids as a sole carbon source and
are defective in in vivo growth in a neutropenic murine model of
bacteremia (Johnson et al., 2015). The role of a functional T2SS
for full virulence ofA. baumannii has been shown inG.mellonella
and murine pulmonary infection models (Harding et al., 2016).
Lipases (LipA, LipH, and LipAN) and the metallopeptidase CpaA
have been identified as T2SS substrates (Elhosseiny et al., 2016;
Harding et al., 2016). Notably, two proteins (LipA and CpaA)
among these secreted proteins require specific chaperones for
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secretion. These chaperones are encoded adjacently to their
cognate effector, and their inactivation abolishes secretion of
LipA and CpaA (Harding et al., 2016).
Acinetobacter baumannii also has a type VI secretion system
(T6SS). The T6SS was first identified in Vibrio cholera and
P. aeruginosa (Mougous et al., 2006; Pukatzki et al., 2006).
Many bacteria use the T6SS to inject effector proteins, providing
a colonization advantage during infection of eukaryotic hosts
(Mougous et al., 2006) or to kill competing bacteria (Basler
et al., 2013). The T6SS leads to DNA release and horizontal
gene transfer in V. cholera, which may contribute to spread
of antibiotic resistance (Borgeaud et al., 2015). The T6SS is
composed of many conserved structural proteins and accessory
factors, and bears a contractile bacteriophage sheath-like
structure forming a needle or spike structure used to penetrate
the target cell (Shneider et al., 2013). Hcp is a structural protein
forming a polymerized tubular structure that is secreted out of
the cell, and VgrGs are involved in attaching effector domains to
the spike, and a proline-alanine-alanine-arginine (PAAR) repeat
protein forms the sharp tip of the distinctive needle-like structure
(Shneider et al., 2013; Zoued et al., 2014).
The presence of T6SS in A. baumannii was initially predicted
by bioinformatic analysis (Weber et al., 2013). Although the role
of T6SS in A. baumannii ATCC 17978 has not been determined
(Weber et al., 2013), research on A. baumannii strain M2 showed
that this strain produces a functional T6SS and that the T6SS
mediates killing of competing bacteria (Carruthers et al., 2013).
Another study showed that the T6SS is active in six pathogenic
strains of A. baumannii (Ruiz et al., 2015). However, the T6SS
seems to play an important role in A. baumannii virulence in
a strain-specific manner (Repizo et al., 2015). They compared
T6SS functionality of several A. baumannii strains, including
ATCC17978 (a type strain), various MDR strains implicated in
hospital outbreaks (Ab242, Ab244, and Ab825), and DSM30011
(a non-clinical isolate). Although the T6SS genomic locus is
present in all of these strains, only DSM30011 has a fully active
T6SS that mediates E. coli killing (Repizo et al., 2015). In addition,
the T6SS of DSM30011 is required for host colonization of
the G. mellonella model organism (Repizo et al., 2015). Similar
results were obtained from a comparative analysis of the genomes
of MDR A. baumannii clinical strains (Wright et al., 2014;
Jones et al., 2015). A. baumannii isolates of a particular clade
exhibit complete loss of the T6SS genomic locus. Therefore,
these results suggest that more extensive investigations are
required to analyze the role of T6SS in A. baumannii virulence,
even though this system seems to play an important role in
A. baumannii virulence in some strains. Notably, one study
showed that several MDR A. baumannii strains have a large, self-
transmissible plasmid that carries negative regulators for T6SS
(Weber et al., 2015b). The T6SS is silenced in plasmid-containing,
antibiotic-resistant cells, whereas plasmid-losing cells have an
active T6SS. Although plasmid-losing cells are capable of T6SS-
mediated killing of competing bacteria, they become susceptible
to antibiotics (Weber et al., 2015b). This result suggests a
molecular switch between T6SS and antibiotic resistance.
The type V system autotransporter Ata has also been
characterized in A. baumannii (Bentancor et al., 2012a).
This is a trimeric membrane protein that mediates biofilm
formation, adherence to extracellular matrix components such
as collagen I, III, and IV, and virulence in a murine systemic
model of Acinetobacter infection (Bentancor et al., 2012a).
Another experiment using a pneumonia model of infection
in immunocompetent and immunocompromised mice showed
that Ata is a vaccine candidate against A. baumannii infections
(Bentancor et al., 2012b). A type IV secretion system present in
the plasmid was bioinformatically identified inA. baumannii (Liu
C. C. et al., 2014), but no experimental evidence describing its
function has been presented.
Penicillin-Binding Protein 7/8 (PBP7/8) and
β-Lactamase PER-1
Although PBPs are commonly involved in resistance to β-
lactam antibiotics, PBP7/8 encoded by the pbpG gene is a
virulence factor in A. baumannii. The pbpGmutant strain grows
similar to its wild-type strain in Luria-Bertani medium, but
the mutant shows reduced growth in human serum and its
survival significantly decreases in rat soft-tissue infection and
pneumonia models (Russo et al., 2009). An investigation of
bacterial morphology using electron microscopy suggested that
loss of PBP7/8 may have affected peptidoglycan structure, which
may affect susceptibility to host defense factors (Russo et al.,
2009).
Interestingly, β-lactamase PER-1 has been suggested to be an
A. baumannii virulence factor. PER-1 is an extended-spectrum-
β-lactamase (ESBL), but this gene is associated with cell adhesion
(Sechi et al., 2004). Nine PER-1-producing strains adhere to the
Caco2 cell lines, whereas all PER-1-negative strains are negative
for cell adhesion (Sechi et al., 2004). Notably, many β-lactamases
are associated with virulence in various pathogenic bacteria, such
as E. coli (Dubois et al., 2009), P. aeruginosa (Moya et al., 2008),
and K. pneumoniae (Sahly et al., 2008). However, no general
mechanisms have been proposed (Beceiro et al., 2013).
Others
Acinetobacter baumannii CipA is a novel plasminogen binding
and complement inhibitory protein that mediates serum
resistance (Koenigs et al., 2016). CipA-binding plasminogen
is converted to active plasmin that degrades fibrinogen and
complement C3b, which contributes to serum resistance of A.
baumannii. Therefore, the cipA mutant strain is efficiently killed
by human serum and also shows a defect in the penetration
of endothelial monolayers (Koenigs et al., 2016). Similar to
CipA, the A. baumannii translation elongation factor Tuf is also
a plasminogen-binding protein. Tuf-binding plasminogen can
be converted to active plasmin, which proteolytically degrades
fibrinogen as well as component C3b (Koenigs et al., 2015).
RecA, which is involved in homologous recombination and the
SOS response, has been identified as an A. baumannii virulence
factor. The recA mutant shows significantly reduced survival
within macrophages and decreases lethality in a mouse model
of systemic infection (Aranda et al., 2011). The surface antigen
protein 1 (SurA1) plays an important role in fitness and virulence
of A. baumannii (Liu D. et al., 2016). Serum resistance of the
surA1 mutant significantly decreases compared with that of
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the wild-type strain CCGGD201101. In the G. mellonella insect
model, a surA1 mutant strain exhibits a lower survival rate and
decreased dissemination (Liu D. et al., 2016).
A growth analysis of 250,000 A. baumannii transposon
mutants within G. mellonella larvae identified 300 genes
required for survival or growth of A. baumannii inside G.
mellonella larvae (Gebhardt et al., 2015). The 300 genes
were classified into six categories of micronutrient acquisition,
cysteine metabolism/sulfur assimilation, aromatic hydrocarbon
metabolism, cell envelope/membrane/wall, stress response genes,
antibiotic resistance, and transcriptional regulation. Among
them, four transcriptional regulators required for growth in
G. mellonella larvae were called the gig (growth in Galleria)
genes. Loss of these genes (gigA-D) led to a significant
defect in both growth within and killing of G. mellonella
larvae (Gebhardt et al., 2015). This study identified stress
proteins, such as UspA, as factors required for growth in
G. mellonella. Another study showed that UspA is essential
for pneumonia and sepsis pathogenesis of A. baumannii
(Elhosseiny et al., 2015). Among the 300 genes, several genes
are involved in aromatic hydrocarbon metabolism (Gebhardt
et al., 2015). Another study showed that GacS, which is a
transcriptional factor that regulates expression of genes, such
as paaE, and is responsible for the phenylacetic acid catabolic
pathway, affects A. baumannii virulence (Cerqueira et al.,
2014). Experiments using a paaE deletion mutant confirmed
the role of aromatic hydrocarbon metabolism in A. baumannii
virulence (Cerqueira et al., 2014), but its molecular mechanism
remains unknown. Interestingly, a recent report showed that
accumulation of phenylacetate in A. baumannii induces rapid
neutrophil influx to a localized site of infection and increases
bacterial clearance (Bhuiyan et al., 2016). They suggested that
phenylacetate is a neutrophil chemoattractant inducing bacterial-
guided neutrophil chemotaxis. This report may reveal a novel
molecular mechanism about the role of the phenylacetic acid
catabolic pathway in A. baumannii virulence.
Biofilm formation plays an important role in immune evasion
by A. baumannii (de Breij et al., 2010), and pili are essential
for A. baumannii adherence to and biofilm formation on abiotic
surfaces as well as virulence (Tomaras et al., 2003, 2008). Notably,
imipenem treatment of the imipenem-resistant A. baumannii
isolate induces expression of important genes responsible for
synthesis of type IV pili (Dhabaan et al., 2015), suggesting that
the ability to overproduce pili confers a biological advantage to
A. baumannii.
Other virulence-related proteins have been identified,
including OmpR/EnvZ (Tipton and Rather, 2016), FhaBC
(Perez et al., 2016), and the resistance-nodulation-division-type
membrane transporter AbeD (Srinivasan et al., 2015), but their
molecular mechanisms remain unknown.
ANTIMICROBIAL RESISTANCE OF
A. BAUMANNII
Acinetobacter baumannii has become one of the most successful
pathogens in modern healthcare because of its amazing
ability to acquire antimicrobial resistance. Several strains
of A. baumannii are highly resistant to most clinically
available antibiotics (Lin and Lan, 2014). A. baumannii has
a number of resistance mechanisms, including β-lactamases,
aminoglycoside-modifying enzymes, eﬄux pumps, permeability
defects, and modifications of target sites. The accumulation of
several resistance mechanisms in A. baumannii has gradually
decreased the number of antibiotic classes available to treat
A. baumannii infections in clinical practice. Table 2 shows the
antibiotic resistance mechanisms found inA. baumannii. We will
discuss the details below.
β-Lactamases
Inactivation of β-lactams by β-lactamases is a major antibiotic
resistance mechanism in A. baumannii. Based on sequence
homology, β-lactamases are grouped into molecular classes,
A, B, C, and D (Jeon et al., 2015). All four classes of β-
lactamases were identified in A. baumannii. Recent studies have
shown that A. baumannii has natural competence to incorporate
exogenous DNA and its genome has foreign DNA at high
frequencies, implying frequent horizontal gene transfer in this
pathogen (Ramirez et al., 2010a; Touchon et al., 2014; Traglia
et al., 2014). Additionally, albumin, a main protein in blood,
enhances natural competence of A. baumannii (Traglia et al.,
2016). Therefore, natural competence of A. baumannii may
contribute to identification of a large number of β-lactamases in
this threatening human pathogen.
Class A β-lactamases inhibited by clavulanate hydrolyze
penicillins and cephalosporins more efficiently than
carbapenems, except for some KPC type enzymes (Jeon
et al., 2015). A number of class A β-lactamases, including TEM,
SHV, GES, CTX-M, SCO, PER, VEB, KPC, and CARB, have been
identified in A. baumannii (Table 2). Some of these enzymes,
such as TEM-1, CARB-4, and SCO-1, are narrow-spectrum
β-lactamases, whereas other enzymes (e.g., PER-1, TEM-92,
CARB-10, SHV-5, PER-2, CTX-M-2, CTX-M-15, VEB-1,
GES-14, and PER-7) are ESBLs. Some carbapenemases, such
as GES-14 and KPC-2, have been detected in A. baumannii
(Moubareck et al., 2009; Bogaerts et al., 2010).
Unlike the serine-dependent β-lactamases (classes A, C, and
D), class B β-lactamases are metallo-β-lactamases (MBLs) that
require zinc or another heavy metal for catalysis (Jeon et al.,
2015). Due to a broad substrate spectrum, MBLs catalyze
the hydrolysis of virtually all β-lactam antibiotics including
carbapenems, but not monobactams (Jeon et al., 2015). A variety
of class B β-lactamases have been identified in A. baumannii
(Table 2).
Class C β-lactamases pose therapeutic problems because
they can confer resistance to cephamycins (cefoxitin and
cefotetan), penicillins, cephalosporins, and β-lactamase inhibitor
combinations, but are not significantly inhibited by clinically
used β-lactamase inhibitors, such as clavulanic acid (Jeon
et al., 2015). Acinetobacter baumannii has an intrinsic AmpC
cephalosporinase (Gordon and Wareham, 2010). An analysis of
23 MDR A. baumannii clinical isolates in Taiwan showed that all
isolates had AmpC-type β-lactamases (Lin et al., 2011a). Several
clinical isolates of A. baumannii have the ampC gene transcribed
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 March 2017 | Volume 7 | Article 55
Lee et al. Biology of Acinetobacter baumannii
TABLE 2 | Resistance mechanisms in Acinetobacter baumannii.
Resistance mechanism Class/subgroup Protein References
β-Lactamases Class A TEM-1 Chen et al., 2006; Adams et al., 2008; Krizova et al., 2013
TEM-92 Endimiani et al., 2007
GES-1 Al-Agamy et al., 2016
GES-5 Al-Agamy et al., 2016
GES-11 Moubareck et al., 2009; Bogaerts et al., 2010; Chihi et al., 2016
GES-12 Bogaerts et al., 2010
GES-14 Bogaerts et al., 2010
PER-1 Jeong et al., 2005; Poirel et al., 2005a; Aly et al., 2016
PER-2 Pasteran et al., 2006
PER-7 Bonnin et al., 2011b
CTX-M-2 Nagano et al., 2004
CTX-M-15 Potron et al., 2011
SCO-1 Poirel et al., 2007
VEB-1 Fournier et al., 2006; Naas et al., 2006; Pasteran et al., 2006;
Adams et al., 2008; Poirel et al., 2009
KPC-2 Martinez et al., 2016
KPC-10 Robledo et al., 2010
CARB-4 Ramirez et al., 2010b
CARB-10 Potron et al., 2009
Class B IMP-1 Tognim et al., 2006
IMP-2 Riccio et al., 2000
IMP-4 Chu et al., 2001
IMP-5 Koh et al., 2007
IMP-6 Gales et al., 2003
IMP-8 Lee M. F. et al., 2008
IMP-11 Yamamoto et al., 2011
IMP-19 Yamamoto et al., 2011
IMP-24 Lee M. F. et al., 2008
VIM-1 Tsakris et al., 2006, 2008; Papa et al., 2009
VIM-2 Yum et al., 2002; Lee M. F. et al., 2008
VIM-3 Lee M. F. et al., 2008
VIM-4 Tsakris et al., 2008; Papa et al., 2009
VIM-11 Lee M. F. et al., 2008
NDM-1 Chen et al., 2011; Pfeifer et al., 2011; Bonnin et al., 2012;
Voulgari et al., 2016
NDM-2 Espinal et al., 2011
NDM-3 Kumar, 2016
SIM-1 Lee et al., 2005
Class C AmpC Bou and Martinez-Beltran, 2000; Corvec et al., 2003; Segal
et al., 2004; Hujer et al., 2005; Heritier et al., 2006; Liu and Liu,
2015
Class D
OXA-2 subgroup OXA-21 Vila et al., 1997
OXA-10 subgroup OXA-128 Giannouli et al., 2009
OXA-20 subgroup OXA-37 Navia et al., 2002
OXA-23 subgroup OXA-23 Heritier et al., 2005b; Naas et al., 2005; Corvec et al., 2007;
Koh et al., 2007; Perez et al., 2007; Valenzuela et al., 2007;
Wang et al., 2007; Adams et al., 2008; Stoeva et al., 2008;
Kohlenberg et al., 2009; Kuo et al., 2010; Mugnier et al., 2010;
Bonnin et al., 2011a; Lee et al., 2011; Lin et al., 2011b; Koh
et al., 2012; Mosqueda et al., 2013; Chagas et al., 2014;
Principe et al., 2014; Li Y. et al., 2015
(Continued)
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TABLE 2 | Continued
Resistance mechanism Class/subgroup Protein References
OXA-133 Mendes et al., 2009
OXA-239 Gonzalez-Villoria et al., 2016
OXA-24 subgroup OXA-24 Bou et al., 2000b; Merino et al., 2010; Acosta et al., 2011;
Pailhories et al., 2016
OXA-25, OXA-26, OXA-27 Afzal-Shah et al., 2001
OXA-40 Heritier et al., 2003; Lolans et al., 2006; Quinteira et al., 2007;
Ruiz et al., 2007
OXA-72 Wang et al., 2007; Lu et al., 2009; Goic-Barisic et al., 2011;
Dortet et al., 2016; Kuo et al., 2016
OXA-143 Higgins et al., 2009
OXA-182 Kim et al., 2010
OXA-51 subgroup OXA-51 Brown et al., 2005; Hu et al., 2007; Ruiz et al., 2007; Adams
et al., 2008; Chen et al., 2010; Fang et al., 2016
OXA-64, OXA-65, OXA-66,
OXA-68, OXA-70, OXA-71
Hamouda et al., 2010; Biglari et al., 2016
OXA-69, OXA-75, OXA-76, OXA-77 Heritier et al., 2005a
OXA-79, OXA-80, OXA-104,
OXA-106∼ OXA-112
Evans et al., 2007
OXA-82, OXA-83, OXA-83, OXA-84 Turton et al., 2006b; Evans et al., 2007
OXA-86, OXA-87 Vahaboglu et al., 2006
OXA-88, OXA-91, OXA-93,
OXA-94, OXA-95, OXA-96
Koh et al., 2007
OXA-92 Tsakris et al., 2007
OXA-113 Naas et al., 2007
OXA-58 subgroup OXA-58 Dijkshoorn et al., 1996; Poirel et al., 2005b; Pournaras et al.,
2006; Chen et al., 2008; Qi et al., 2008; Donnarumma et al.,
2010; Gogou et al., 2011; Ravasi et al., 2011; Hou and Yang,
2015
OXA-96 Koh et al., 2007
OXA-97 Poirel et al., 2008
OXA-143 subgroup OXA-253 de Sa Cavalcanti et al., 2016
OXA-235 subgroup OXA-235 Higgins et al., 2013
Efflux pumps Resistance-nodulation-division
superfamily
AdeABC Magnet et al., 2001; Marchand et al., 2004; Peleg et al., 2007;
Ruzin et al., 2007; Lin et al., 2015; Sun et al., 2016
AdeFGH Coyne et al., 2010; He X. et al., 2015
AdeIJK Damier-Piolle et al., 2008
Major facilitator superfamily TetA Ribera et al., 2003a
TetB Vilacoba et al., 2013
CmlA Coyne et al., 2011
CraA Roca et al., 2009
AmvA Rajamohan et al., 2010
AbaF Sharma et al., 2016
Multidrug and toxic compound
extrusion family
AbeM Su et al., 2005
Small multidrug resistance
family
AbeS Srinivasan et al., 2009
Other efflux pumps EmrAB-TolC Nowak-Zaleska et al., 2016
A1S_1535, A1S_2795, and
ABAYE_0913
Li L. et al., 2016
Permeability defects Porin OmpA Smani et al., 2014; Wu et al., 2016
CarO Mussi et al., 2005, 2007; Siroy et al., 2005; Catel-Ferreira et al.,
2011; Jin et al., 2011
(Continued)
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TABLE 2 | Continued
Resistance mechanism Class/subgroup Protein References
Omp22-33 Bou et al., 2000a
Omp33-36 del Mar Tomas et al., 2005
Omp37 Quale et al., 2003
Omp43 Dupont et al., 2005
Omp44 Quale et al., 2003





AAC3 (aacC1, aacC2) Nemec et al., 2004
AAC(6′) (aacA4) Doi et al., 2004; Cho et al., 2009; Zhu et al., 2009; Lin et al.,
2010; Lin M. F. et al., 2013; Bakour et al., 2014
Aminoglycoside
adenyltransferases
ANT(2′′) (aadB) Nemec et al., 2004
ANT(3′′) (aadA1) Cho et al., 2009; Lin et al., 2010; Lin M. F. et al., 2013
Aminoglycoside
phosphotransferases
APH(3′) (aphA1) Gallego and Towner, 2001
APH(3′′) Cho et al., 2009
Alteration of target sites Change of penicillin binding
protein(PBP)
PBP2 Gehrlein et al., 1991
16S rRNA methylation ArmA Yu et al., 2007; Cho et al., 2009; Karthikeyan et al., 2010;
Brigante et al., 2012; Hong et al., 2013; Bakour et al., 2014;
Tada et al., 2014
Ribosomal protection TetM Ribera et al., 2003b
DNA gyrase GyrA/ParC Higgins et al., 2004
Dihydrofolate reductase DHFR Mak et al., 2009; Lin M. F. et al., 2013
FolA Mak et al., 2009




Trm Chen et al., 2014; Trebosc et al., 2016
1-Acyl-sn-3-phosphate
acyltransferase
PlsC Li X. et al., 2015
Peptidase C13 family Abrp Li X. et al., 2016
Cell division proteins BlhA, ZipA, ZapA, and FtsK Knight et al., 2016
SOS response RecA Aranda et al., 2011, 2014; Norton et al., 2013
from a strong promoter contained within a putative insertion
sequence element (ISAba1-like sequence), which results in high
resistance to ceftazidime (Corvec et al., 2003; Segal et al., 2004).
This sequence has been identified in ceftazidime-resistant A.
baumannii isolates, but is absent in ceftazidime-susceptible A.
baumannii isolates (Heritier et al., 2006).
Class D β-lactamases are called OXAs (oxacillinases), because
they commonly hydrolyze isoxazolylpenicillin oxacillin much
faster than benzylpenicillin (Jeon et al., 2015). More than 400
OXA-type enzymes have been identified and many variants
actually possess carbapenemase activity. The presence of
carbapenem-hydrolyzing class D β-lactamases or MBLs is one of
the major carbapenem resistance mechanisms in A. baumannii
(Lin and Lan, 2014). The subgroups of carbapenem-hydrolyzing
OXAs, such as the OXA-23, OXA-24, OXA-51, and OXA-58
subgroups, are prevalent in A. baumannii (Table 2). The OXA-
23 enzyme was first identified in an A. baumannii isolate in
the United Kingdom in 1985 (Perez et al., 2007). The blaOXA-23
gene has been disseminated worldwide, and the frequency of
OXA-23-producing A. baumannii strains is significantly high
(Mugnier et al., 2010; Al-Agamy et al., 2016). One recent report
from Lebanon showed 76.5% of 119 A. baumannii isolates are
resistant to carbapenems, and OXA-23 β-lactamases have been
found in 82 isolates (Al Atrouni et al., 2016). Insertion of
ISAba1 in the blaOXA-23 promoter sequence has been reported
to be associated with overexpression of blaOXA-23, blaOXA-51, or
blaOXA-58 in A. baumannii (Turton et al., 2006a). One report
from India showed that blaOXA-51 and blaOXA-23 were present
in all 103 carbapenem-resistant A. baumannii isolates and almost
80% of the isolates had ISAba1 upstream of the blaOXA-23 gene,
indicating the prevalence of the ISAba1 insertion (Vijayakumar
et al., 2016).
Efflux Pumps
Eﬄux pumps are associated with resistance against many
different classes of antibiotics, such as imipenem (Hu et al.,
2007) and tigecycline (Peleg et al., 2007; Ruzin et al.,
2007), in A. baumannii. Reversal of antibiotic resistance by
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eﬄux pump inhibitors, such as 1-(1-naphthylmethyl)-piperazine
and carbonyl cyanide 3-chlorophenyl-hydrazone, supports the
importance of eﬄux pumps in A. baumannii antibiotic resistance
(Pannek et al., 2006; Deng et al., 2014). Four categories of eﬄux
pumps, such as the resistance-nodulation-division superfamily,
the multidrug and toxic compound extrusion family, the major
facilitator superfamily, and the small multidrug resistance
family transporters, are related to antimicrobial resistance in A.
baumannii (Table 2; Lin and Lan, 2014).
AdeABC in the resistance-nodulation-division superfamily
is associated with aminoglycoside resistance (Magnet et al.,
2001) and with decreasing susceptibility to tigecycline (Ruzin
et al., 2007) and non-fluoroquinolone antibiotics (Higgins
et al., 2004). AdeABC seems to be cryptic in wild-type A.
baumannii because of stringent control by the AdeRS two-
component system (Marchand et al., 2004), but point mutations
or insertion of the ISAba1 sequence in the adeS gene leads
to overexpression of AdeABC (Marchand et al., 2004; Sun
et al., 2012, 2016; Hammerstrom et al., 2015). Cell density
(Fernando and Kumar, 2012) and the BaeSR two-component
system (Lin et al., 2014, 2015), which is involved in an envelope
stress response, also seem to regulate transcription of the adeA
gene and thus affect tigecycline susceptibility. Other resistance-
nodulation-division type eﬄux pumps, such as AdeFGH and
AdeIJK, are synergistically associated with tigecycline resistance
(Damier-Piolle et al., 2008). AdeFGH and AdeIJK expression is
regulated by the LysR-type transcriptional regulator AdeL and
the TetR-type transcriptional regulator AdeN (Coyne et al., 2010;
Rosenfeld et al., 2012).
Acinetobacter baumannii clinical isolates possess a strong
ability to form biofilms (Rodriguez-Bano et al., 2008). Notably,
the subinhibitory concentrations of antibiotics encountered by
low-dose therapy seem to strongly induce biofilm formation
(Kaplan, 2011). A recent result revealed the mechanism.
Overexpression of the AdeFGH eﬄux pump by low-dose
antimicrobial therapy increases the synthesis and transport of
autoinducer molecules, which induce biofilm formation (He X.
et al., 2015). These results suggest a link between low-dose
antimicrobial therapy and a high risk for biofilm infections
caused by A. baumannii.
CmlA and CraA are major facilitator superfamily eﬄux
pumps related with chloramphenicol (Fournier et al., 2006; Roca
et al., 2009), and TetA is associated with tetracycline resistance
(Ribera et al., 2003a). The novel eﬄux pump AmvA mediates
resistance to different classes of antibiotics, disinfectants,
detergents, and dyes, such as erythromycin, acriflavine,
benzalkonium chloride, and methyl viologen (Rajamohan et al.,
2010). AbaF was recently identified as a novel eﬄux pump
associated with fosfomycin resistance (Sharma et al., 2016).
AbeM is in the multidrug and toxic compound extrusion
family and confers resistance to imipenem and fluoroquinolones
(Su et al., 2005). AbeS is the small multidrug resistance
family transporter and affects resistance to various antimicrobial
compounds. Deletion of the abeS gene results in increased
susceptibility to various antimicrobial compounds, such as
chloramphenicol, nalidixic acid, and erythromycin (Srinivasan
et al., 2009).
Some other eﬄux pumps, such as MacAB-TolC (Kobayashi
et al., 2001) and EmrAB-TolC (Lomovskaya and Lewis, 1992),
have been well described in E. coli, but their role in A. baumannii
has been recently explored. The EmrAB-TolC eﬄux pump is
also present in A. baumannii where it conferred resistance to
netilmicin, tobramycin, and imipenem (Nowak-Zaleska et al.,
2016). Another report identified three novel eﬄux pumps
(A1S_1535, A1S_2795, and ABAYE_0913) inA. baumannii using
multiplexed phenotypic screening (Li L. et al., 2016). A1S_1535
confers resistance to various antibiotics, including gentamicin,
kanamycin, chloroxylenol, oxytetracycline, 1,10-phenanthroline,
and chloramphenicol (Li L. et al., 2016). A1S_2795 is the
first major facilitator superfamily eﬄux pump found to confer
resistance to the sulphonamide sulfathiazole, and ABAYE_0913
is associated with resistance to chloramphenicol and fusidic acid
(Li L. et al., 2016).
Permeability Defects
A change in envelope permeability can influence antibiotic
resistance. For example, porins form channels that allow
transport of molecules across the outer membrane and play a
significant role in A. baumannii virulence (Table 1). Because
porins affect membrane permeability, they also play a significant
role in the mechanism of resistance. Reduced expression of some
porins, including CarO (Mussi et al., 2005, 2007; Siroy et al.,
2005; Catel-Ferreira et al., 2011; Jin et al., 2011), Omp22-33 (Bou
et al., 2000a), Omp33-36 (del Mar Tomas et al., 2005; Hood
et al., 2010), Omp37 (Quale et al., 2003), Omp43 (Dupont et al.,
2005), Omp44 (Quale et al., 2003), and Omp47 (Quale et al.,
2003), is associated with carbapenem resistance in A. baumannii.
Loss of Omp29 in A. baumannii producing OXA-51-like or
OXA-23-like carbapenemases results in increased imipenem
resistance (Jeong et al., 2009; Fonseca et al., 2013). OmpA is
also related with resistance to aztreonam, chloramphenicol, and
nalidixic acid (Smani et al., 2014). One study showed that OmpA
and CarO physically interact with OXA-23 carbapenemase, and
these interactions are associated with antibiotic resistance (Wu
et al., 2016). These results provide a novel view to increase
understanding of bacterial antibiotic resistance mechanisms.
Besides outermembrane proteins, envelope components, such
as LPS and peptidoglycans, also affects antibiotic resistance of
A. baumannii. Loss or modification of LPS decreases membrane
integrity and increases colistin resistance in A. baumannii
(Adams et al., 2009; Moffatt et al., 2010).
Aminoglycoside-Modifying Enzymes
Aminoglycoside-modifying enzymes are the major mechanism
by which A. baumannii confers resistance to aminoglycosides.
Aminoglycoside-modifying enzymes can be classified into
acetyltransferases, adenyltransferases, and phosphotransferases.
These enzymes are typically present on transposable elements
and are transferred among pathogenic bacteria (Lin and Lan,
2014). Several reports show that many MDR A. baumannii
isolates produce a combination of aminoglycoside-modifying
enzymes (Gallego and Towner, 2001; Nemec et al., 2004). A study
from China identified a MDR A. baumannii strain carrying four
aminoglycoside-modifying enzymes (Zhu et al., 2009). Another
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12 March 2017 | Volume 7 | Article 55
Lee et al. Biology of Acinetobacter baumannii
study from Greece reported that all A. baumannii strains contain
aminoglycoside-modifying enzymes (Ploy et al., 1994), indicating
the high prevalence of these enzymes in A. baumannii.
Alteration of Target Sites
Modifications in antibiotic target sites for antibiotics can
induce antibiotic resistance in A. baumannii. In the absence
of other known resistance mechanisms, only overexpression
of altered PBPs with a low affinity for imipenem induce
imipenem resistance (Gehrlein et al., 1991). Quinolone resistance
is associated with modifications in GyrA (one subunit of
DNA gyrase) and ParC (one subunit of topoisomerase IV)
in epidemiologically unrelated A. baumannii isolates (Vila
et al., 1995). Acinetobacter baumannii TetM, which has
100% homology with S. aureus TetM, has been proposed to
be associated with tetracycline resistance through ribosomal
protection (Ribera et al., 2003b). Similar to other pathogenic
bacteria, dihydrofolate reductases (DHFR and FolA) responsible
for trimethoprim resistance have been found in nosocomialMDR
A. baumannii isolates (Mak et al., 2009; Lin M. F. et al., 2013;
Taitt et al., 2014). The 16S rRNAmethylase ArmA responsible for
aminoglycoside resistance is also found in many A. baumannii
strains and always coexists with OXA type carbapenemases such
as OXA-23 (Yu et al., 2007; Cho et al., 2009; Karthikeyan et al.,
2010; Brigante et al., 2012; Hong et al., 2013; Bakour et al.,
2014; Tada et al., 2014; Hasani et al., 2016). As described above,
many studies have shown that modifications or/and loss of LPS
decrease the susceptibility of A. baumannii to many clinical
important antibiotics, such as colistin.
Others
AdeABC is associated with decreased susceptibility to tigecycline
(Ruzin et al., 2007). However, some clinical isolates without
overexpressed AdeABC, AdeFGH, and AdeIJK have decreased
susceptibility to tigecycline. Several reports have suggested
the mechanism. One study analyzed eight A. baumannii
clinical isolates and revealed that the deletion mutation in the
trm gene, which encodes S-adenosyl-L-methionine-dependent
methyltransferase, decreases susceptibility to tigecycline (Chen
et al., 2014). The same result was reported using a highly efficient
and versatile genome-editing platform enabling markerless
modification of the A. baumannii genome. Deletion of AdeR,
a transcription factor that regulates AdeABC eﬄux pump
expression in tigecycline-resistant A. baumannii, reduces the
MIC of tigecycline. However, 60% of the clinical isolates
remained nonsusceptible to tigecycline after the adeR deletion
according to a highly efficient and versatile genome-editing
platform (Trebosc et al., 2016). Whole-genome sequencing in
two tigecycline-resistant adeR deletion strains revealed that a
mutation in the trm gene makes the adeR mutant resistant
to tigecycline. In addition, a trm disruption was identified in
most tigecycline-resistant clinical isolates (Trebosc et al., 2016).
However, its exact mechanism was not determined. Another
study revealed that a frameshift mutation in plsC, encoding 1-
acyl-sn-glycerol-3-phosphate acyltransferase, is associated with
decreased susceptibility to tigecycline (Li X. et al., 2015).
The abrp gene, which encodes the peptidase C13 family,
is associated with decreased susceptibility to tetracycline,
minocycline, doxycycline, tigecycline, chloramphenicol, and
fosfomycin (Li X. et al., 2016). Deletion of abrp increases cell
membrane permeability, displays slower cell growth rate, and
confers reduced susceptibility to these antibiotics (Liu X. et al.,
2016). However, its exact mechanism was not determined. Some
genes involved in cell division, including blhA, zipA, zapA,
and ftsK, are associated with intrinsic β-lactam resistance in A.
baumannii (Knight et al., 2016).
Increased expression of mutagenesis-related genes, such as
the SOS response genes, is a well-understood mechanism of E.
coli and other bacteria to obtain antibiotic resistance (Cirz and
Romesberg, 2007). Acinetobacter baumannii also seems to have
an inducible DNA damage response in which RecA plays a major
regulatory role and seems to acquire antibiotic resistances under
clinically relevant DNA-damaging conditions (Aranda et al.,
2011, 2014; Norton et al., 2013). Furthermore, RecA is involved
in the A. baumannii pathogenicity (Aranda et al., 2011).
PROSPECTIVE TREATMENT OPTIONS
Although carbapenems are effective antibiotics to treat A.
baumannii infections (Cisneros and Rodríguez-Baño, 2002;
Turner et al., 2003), the rate of carbapenem-resistant A.
baumannii isolates has been increasing gradually (Mendes
et al., 2010; Kuo et al., 2012; Su et al., 2012). Only a few
effective antibiotic options are available to treat MDR
A. baumannii infections (Gordon and Wareham, 2009;
Lee J. H. et al., 2015, 2016). To combat MDR or pandrug-
resistant (PDR) A. baumannii, which are resistant to all
available antibiotics, combination therapies, including
colistin/imipenem, colistin/meropenem, colistin/rifampicin,
colistin/tigecycline, colistin/sulbactam, colistin/teicoplanin, and
imipenem/sulbactam, have been extensively studied. Prospective
treatment options of Acinetobacter baumannii infections
are summarized in Table 3. We will discuss the most recent
published reports.
Carbapenems and β-Lactamase Inhibitors
Carbapenems, including imipenem, meropenem, and
doripenem, have generally been considered the agents to
treat A. baumannii infections, due to their effective activity
against this organism and their favorable safety (Doi et al.,
2015). However, the decreased susceptibility of A. baumannii
to carbapenems has forced clinicians and researchers to
explore alternative therapeutic approaches (Doi et al., 2015).
Because carbapenem-resistant A. baumannii strains are often
resistant to all other commonly used antibiotics as well, these
strains remain susceptible to only limited antibiotics, such as
minocycline/tigecycline and polymyxins (colistin and polymyxin
B; Lin and Lan, 2014; Doi et al., 2015). Carbapenem therapies
combined with a few effective antibiotics was extensively tested
and many cases showed a synergistic effect against A. baumannii
infections (Table 3). However, recent increase of tigecycline-
or colistin-resistant A. baumannii increasingly poses a serious
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threat to public health worldwide (Peleg et al., 2007; Hornsey
et al., 2010; Cai et al., 2012).
Sulbactam is a β-lactamase inhibitor and also has affinity for
penicillin-binding proteins of A. baumannii (Rafailidis et al.,
2007; Doi et al., 2015). Combined therapy of ampicillin with
sulbactam is effective for treating bloodstream infections
due to MDR A. baumannii (Smolyakov et al., 2003).
Ampicillin/sulbactam/carbapenem combination therapy is also
effective for treating MDR A. baumannii bacteremia (Kuo et al.,
2007) and skin and soft tissue infection of carbapenem-resistant
A. baumannii (Hiraki et al., 2013), but not in ventilator-
associated pneumonia (Kalin et al., 2014). The population
pharmacokinetics and pharmacodynamics of sulbactam were
determined in critically ill patients with severe sepsis caused by
A. baumannii (Jaruratanasirikul et al., 2016) and in patients with
impaired renal function (Yokoyama et al., 2015). Another β-
lactamase inhibitor tazobactam increases the activity of peptide
antibiotics, such as colistin and daptomycin, in a murine model
of A. baumannii pneumonia (Sakoulas et al., 2016). The authors
suggested that β-lactamase inhibitors may exert similar effects in
potentiating peptide antibiotics, because of structural similarities
between β-lactamase inhibitors and peptide antibiotics (Sakoulas
et al., 2016).
Minocycline/Tigecycline
Minocycline, is a broad-spectrum tetracycline antibiotic that
has been proposed for treating drug-resistant A. baumannii
based on its high degree of susceptibility to this drug and
its favorable pharmacokinetic profile (Ritchie and Garavaglia-
Wilson, 2014). The mean susceptibility rate of A. baumannii to
minocycline is approximately 80% worldwide (Castanheira et al.,
2014). Therefore, minocycline therapy has high treatment success
rates and good tolerability (Ritchie andGaravaglia-Wilson, 2014).
However, since the introduction of minocycline, approximately
20% of A. baumannii isolates are not susceptible to minocycline.
The TetB eﬄux pump is the main determinants of minocycline
resistance (Vilacoba et al., 2013). Minocycline therapy combined
with colistin is effective for treating minocycline-resistant A.
baumannii infections (Yang et al., 2016), and minocycline
therapy combined with rifampicin, colistin, or imipenem has a
synergistic effect in most of isolates without the tetB gene, but
combined therapies are not synergistic in isolates with the tetB
gene (Rodriguez et al., 2015).
Tigecycline is the first glycylcycline class antibiotic that
exhibits bacteriostatic activity by binding to the 30S ribosomal
subunit, and is active against A. baumannii infections (Pachon-
Ibanez et al., 2004; Anthony et al., 2008; Koomanachai et al.,
2009). Tigecycline shows a synergistic effect with some classes
of antibiotics, such as amikacin (Moland et al., 2008) and
colistin (Mutlu Yilmaz et al., 2012). However, limitations of
tigecycline use have emerged with its increasing use. Tigecycline
is less effective than imipenem to treat pneumonia in a
murine pneumonia model (Pichardo et al., 2010). β-Lactam
or carbapenem instead of tigecycline was recommended for A.
baumannii infections with tigecycline MIC of more than 2 mg/L,
due to high mortality from the tigecycline treatment (Curcio
and Fernandez, 2008). In a study of 266 patients with MDR
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A. baumannii infections, tigecycline-based therapy was not more
effective than non-tigecycline-based therapies (Lee Y. T. et al.,
2013). Tigecycline resistance associated with overexpression of
eﬄux pumps, such as AdeABC, has been reported in clinical
isolates of A. baumannii (Peleg et al., 2007; Ruzin et al., 2007;
Hornsey et al., 2010, 2011). Multiple MDR A baumannii clones
resistant to tigecycline have been reported in many medical
centers (Navon-Venezia et al., 2007). Therefore, tigecycline can
only be used in limited cases for treatingA. baumannii infections.
Polymyxins (Colistin and Polymyxin B)
Polymyxins are a group of polycationic peptide antibiotics that
were discovered more than 60 years ago and exhibit potent
efficacy against most Gram-negative bacteria (Liu Q. et al.,
2014; Lee C. R. et al., 2016). Among all five polymyxins (A–
E), only polymyxin B and E (colistin) with a one amino acid
difference are used clinically. Colistin is a key component
of combination therapies used to treat MDR A. baumannii
infections (Cai et al., 2012). The rate of colistin resistance (10.4%)
in MDR A. baumannii isolates is lower than that of rifampicin
(47.8%) or tigecycline (45.5%) resistance (Chang et al., 2012).
Similar results were reported in another study (Muthusamy
et al., 2016). Therefore, colistin seems to be the only effective
antimicrobial agent against MDR A. baumannii infections. Many
colistin-based combined therapies, including colistin/rifampicin
(Liang et al., 2011; Aydemir et al., 2013), colistin/minocycline
(Liang et al., 2011), colistin/carbapenem (Liang et al., 2011;
Batirel et al., 2014; Liu X. et al., 2016), colistin/sulbactam
(Batirel et al., 2014), colistin/tigecycline (Principe et al., 2009;
Ozbek and Senturk, 2010; Sheng et al., 2011; Peck et al., 2012),
colistin/daptomycin (Cirioni et al., 2016), colistin/fusidic acid
(Bowler et al., 2016; Fan et al., 2016), and colistin/teicoplanin
(Wareham et al., 2011; Cirioni et al., 2016), are synergistic
in vivo or in vitro against A. baumannii infections. Colistin
therapy combined with rifampin or fusidic acid seems to
be the most effective for treating a MDR A. baumannii in
a murine thigh-infection model (Fan et al., 2016). Another
report comparing colistin/daptomycin, colistin/imipenem, and
imipenem/ertapenem showed that the daptomycin-colistin
combination was the most effective (Cordoba et al., 2015).
Unfortunately, the emergence of colistin-resistant A.
baumannii strains has increased worldwide (Cai et al., 2012).
The mechanisms of colistin resistance include loss of LPS
(Moffatt et al., 2010) and the addition of phosphoethanolamine
to LPS by the PmrAB two-component system (Adams et al.,
2009). Mutations in pmrA and pmrB activate pmrC, which adds
phosphoethanolamine to the hepta-acylated form of lipid A
(Beceiro et al., 2011). Interestingly, an investigation of the in
vitro activities of various antimicrobial combinations against
colistin-resistant A. baumannii showed that the most effective
combinations against colistin-resistantA. baumannii are colistin-
rifampin and colistin-teicoplanin, indicating that colistin is the
most common constituent of antimicrobial combinations
even against colistin-resistant A. baumannii (Bae et al., 2016).
Similarly, minocycline therapy in combination with colistin
is effective to treat infections caused by minocycline-resistant
A. baumannii. Minocycline/colistin therapy significantly
improves survival of mice infected with minocycline-resistant A.
baumannii and reduces the number of bacteria present in the
lungs of mice (Yang et al., 2016).
A urinary tract Enterococcus faecalis isolate that apparently
requires vancomycin to grow was reported in 1994, and
this phenomenon is called “antimicrobial agent dependence.”
Colistin dependence was reported in an A. baumannii–A.
calcoaceticus complex (Hawley et al., 2007). Partial colistin
dependence has been detected in several LPS-deficient strains
with mutations in lpxA, lpxC, and lpxD (Garcia-Quintanilla
et al., 2015). Many colistin-susceptible A. baumannii isolates
develop colistin dependence in vitro after exposure to colistin
(Hong et al., 2016). Although the clinical implication of
colistin dependence and its molecular mechanism remain
unclear, it is interesting that patients with colistin-dependent
A. baumannii isolates show a high rate of treatment failure
(Hong et al., 2016).
Unlike colistin, polymyxin B is not converted from a prodrug
form into an active form; thus, plasma concentrations of
polymyxin B more quickly reach target levels (Sandri et al.,
2013). In addition, polymyxin B is available for direct parenteral
administration (Zavascki et al., 2007). Despite the favorable
pharmacokinetics of polymyxin B, dose-related nephrotoxicity
limits the concentration of polymyxin B used in combination
therapy (Dubrovskaya et al., 2015). Therefore, almost all studies
on polymyxins are carried out for colistin. However, because
some carbapenems have comparatively safer dose modulation
to optimize killing during combination therapy (Cannon et al.,
2014), several studies have analyzing the pharmacodynamics of
carbapenems in combination with polymyxin B (Lenhard et al.,
2016a,b; Rao et al., 2016a). One study showed that intensified
meropenem dosing combined with polymyxin B is a good
strategy to treat carbapenem-resistant A. baumannii, regardless
of the meropenem MIC (Lenhard et al., 2016a). Combination
therapy with doripenem and polymyxin B also showed similar
results. Early aggressive dosing of doripenem combined with
polymyxin B is effective for treating heteroresistantA. baumannii
infections (Rao et al., 2016a). A combined pharmacodynamics
analysis of four different carbapenems with polymyxin B showed
that doripenem, meropenem, or imipenem display similar
pharmacodynamics in combination, and the decision to use
carbapenem in combination with polymyxin B is usually based
on toxicodynamic profiles (Lenhard et al., 2016b). Polymyxin
B also shows good bactericidal activity in combination with
high tigecycline concentrations (Hagihara et al., 2014; Rao
et al., 2016b). Therefore, polymyxin B combination therapies
seem to be one of the most promising options for minimizing
the emergence of polymyxin resistance. Increasing the dose
intensity of polymyxin B amplifies polymyxin B resistance in A.
baumannii (Cheah et al., 2016; Tsuji et al., 2016). In conclusion,
although polymyxin B displays dose-related nephrotoxicity, it is
a potential therapeutic alternative to colistin when use together
with intensified doses of other antibiotics. Large-scale screening
of Streptomyces secondary metabolites was performed to develop
a novel combination therapy using minimal concentrations of
polymyxin B, and the reliable polymyxin synergist netropsin
was identified (Chung et al., 2016). Survival of G. mellonella
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infected with colistin-resistant clinical A. baumannii isolates is
significantly higher when treated with polymyxin B combined
with netropsin than when treated with polymyxin B or netropsin
alone (Chung et al., 2016).
Other Antibiotics
Trimethoprim-sulfamethoxazole is a two antibiotics
combination that exerts a synergistic effect by inhibiting
successive steps in the folate synthesis pathway against a
number of bacteria (Wormser et al., 1982). The in vitro
killing activity of trimethoprim-sulfamethoxazole against
carbapenem-resistant A. baumannii was recently studied.
Trimethoprim-sulfamethoxazole alone effectively kills all
carbapenem-resistant A. baumannii strains and trimethoprim-
sulfamethoxazole combined with colistin also rapidly kills
all strains for up to 24 h (Nepka et al., 2016). These
results suggest that trimethoprim-sulfamethoxazole might
be an effective therapy for severe carbapenem-resistant
A. baumannii infections. Plazomicin is a next-generation
aminoglycoside synthetically derived from sisomicin that
enhances activity against many MDR Gram-negative bacteria
(Garcia-Salguero et al., 2015). A synergistic effect was observed
with carbapenems along with plazomicin during treatment
of A. baumannii infections (Garcia-Salguero et al., 2015),
indicating the potential utility of plazomicin combined with
carbapenems.
The inducible DNA damage response in A. baumannii
plays an important role in acquiring antibiotic resistance
under clinically relevant DNA-damaging conditions (Aranda
et al., 2011, 2014; Norton et al., 2013). The aminocoumarin
novobiocin is a well-established antimicrobial agent that
inhibits the DNA damage response in Gram-positive
bacteria by interfering with ATPase activity of DNA gyrase
(Schroder et al., 2013). One study showed that novobiocin
also inhibits acquisition of antimicrobial resistance in MDR
A. baumannii through DNA damage-induced mutagenesis
(Jara et al., 2015).
Non-antibiotic Therapies: Phage and
Others
The worldwide spread of MDR pathogens has renewed interest
in the therapy using bacteriophage, which is a virus that infects
and lyses bacteria. Various lytic A. baumannii bacteriophages,
such as vB_Ab-M-G7 (Kusradze et al., 2016) and Bφ-C62 (Jeon
et al., 2016), have been used to treat infections caused by
MDR A. baumannii. Bacteriophage-encoded endolysin has also
received attention. Endolysin is a lytic enzyme that degrades the
cell wall of bacterial hosts and shows promise as a novel class
of antibacterials with a unique mode of action (Defraine et al.,
2016). For example, endolysin from A. baumannii bacteriophage
ØABP-01 degrades the crude cell wall of A. baumannii strains
and elevates antibacterial activity when combined with colistin
(Thummeepak et al., 2016). However, most Gram-negative
pathogens are generally not susceptible to endolysins, due to their
protective outer membrane (Lee et al., 2013a). To overcome this
problem, endolysins have recently been engineered with specific
outer membrane-destabilizing peptides to obtain the ability to
penetrate outer membrane and these engineered endolysins
are called “artilysins” (Rodriguez-Rubio et al., 2016). Several
engineered artilysins have been developed to combat MDR
A. baumannii and show highly effective antimicrobial activity
against A. baumannii (Briers et al., 2014; Yang et al., 2015;
Defraine et al., 2016; Thandar et al., 2016). These results suggest
that artilysins can be a treatment option for MDR A. baumannii.
The diversity of the phage population was determined by analysis
of viromes, endolysins, and CRISPR spacers (Davison et al.,
2016). These results can be used to assist in finding an effective
endolysin for combating MDR A. baumannii. Various peptides,
such as American alligator plasma peptide (Barksdale et al., 2016)
and antimicrobial peptide dendrimer G3KL (Pires et al., 2015),
have in vitro antimicrobial activity against MDR A. baumannii.
However, the use of antimicrobial enzymes or peptides also
has some important problems, such as their short half-life in
serum and high production costs compared with those of smaller
molecules.
An in silico analysis predicted that OXA-58, OXA-23, and
OXA-83 are translocated to the periplasm via the Sec system
(Liao et al., 2015; Chiu et al., 2016). A SecA inhibitor (rose
bengal) inhibits periplasmic translocation of these carbapenem-
hydrolyzing class D β-lactamases, indicating that these β-
lactamases are selectively released via a Sec-dependent system
(Liao et al., 2015; Chiu et al., 2016). Imipenem or meropenem
combined with rose bengal shows synergistic effects for
carbapenem-resistant A. baumannii clinical isolates (Chiu et al.,
2016). Similarly, β-aminoketone (MD3), an inhibitor of bacterial
type I signal peptidases that cleaves the amino-terminal signal
peptides of translocated proteins, shows a synergistic effect when
combined with colistin against colistin-resistant A. baumannii
strains (Martinez-Guitian et al., 2016).
Bulgecin A is a natural product of P. mesoacidophila and a
lytic transglycosylase inhibitor that works synergistically with
β-lactams (Skalweit and Li, 2016). Bulgecin A restores the
efficacy of meropenem in suppressing growth of carbapenem-
resistant A. baumannii strains, suggesting that Bulgecin
A may be an adjunctive compound to extend the life of
carbapenems against A. baumannii infections (Skalweit and
Li, 2016). Similarly, farnesol, a natural product of Candida
albicans for quorum-sensing, disrupts A. baumannii cell
membrane integrity, alters cell morphology, and increases
sensitivity of MDR A. baumannii strains to colistin (Kostoulias
et al., 2015). Many herbal active compounds have potent
antibacterial activities against many bacteria including
carbapenem-resistant A. baumannii (Lin et al., 2015). For
example, oleanolic acid is a triterpenoid compound that widely
exists in food, medicinal herbs, and many plants and can
potently inhibit various pathogenic bacteria. One study showed
that oleanolic acid increases aminoglycoside uptake by changing
membrane permeability and energy metabolism in A. baumannii
(Shin and Park, 2015).
Cyanide 3-chlorophenylhydrazone (CCCP) is an eﬄux pump
inhibitor that decreases theMIC of colistin in colistin-susceptible
and colistin-resistant A. baumannii strains (Park and Ko, 2015;
Ni et al., 2016). Other eﬄux pump inhibitors, such as ABEPI1
and ABEPI2, inhibit eﬄux-mediated minocycline tolerance of
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A. baumannii. Adding these compounds during growth in
human serum leads to the accumulation of minocycline within
A. baumannii and inhibits eﬄux potential of the bacterium
(Blanchard et al., 2014).
Gallium is a semi-metallic element in group 13 of the periodic
table that binds to biological complexes containing Fe3+ and
disrupts essential redox-driven biological processes (Bernstein,
1998). Gallium has been used as a simple inorganic or organic
salt or complexed with organic compounds. Several studies have
shown that gallium nitrate or gallium protoporphyrin IX could
be a viable therapeutic option for treating MDR A. baumannii
(Antunes et al., 2012; Arivett et al., 2015). Some D-amino acids,
such as D-His and D-Cys, inhibit bacterial growth, biofilm
formation, and adherence to eukaryotic cells in A. baumannii
(Rumbo et al., 2016).
Probiotics are “live microorganisms that confer a health
benefit on the host when administered in adequate amounts”
(Reid et al., 2005) and assist in protecting against MDR
A. baumannii infections. For example, the ability of the
probiotic Bifidobacterium breve to protect against MDR A.
baumannii infections has been investigated (Asahara et al.,
2016). This probiotic markedly potentiates protection against
fatal intestinal infections caused by MDR A. baumannii
(Asahara et al., 2016). With probiotics, immunomodulators,
such as lysophosphatidylcholine (Parra Millan et al.,
2016) and macrolide antibiotics such as clarithromycin
(Konstantinidis et al., 2016), can reduce A. baumannii
infection severity by stimulating the immune response,
when combined with antibiotics such as colistin, tigecycline, or
imipenem.
CONCLUSION
The number of studies about A. baumannii is increasing
dramatically because of its increasing clinical importance. Use
of animal models has produced important data regarding
virulence factors that contribute to A. baumannii pathogenesis.
Notably, some studies on metal acquisition and protein secretion
systems are interesting. Besides iron acquisition systems such as
acinetobactin, the discovery of zinc and manganese acquisition
systems in A. baumannii broadens our understanding of A.
baumannii pathogenesis. More extensive studies on various
protein secretion systems present in A. baumannii are required.
About 300 genes required for in vivo survival of A. baumannii
were identified using transposon screening inG.mellonella larvae
(Gebhardt et al., 2015). Because many of these genes were not
known to be associated with A. baumannii pathogenesis, more
detailed studies are required to determine whether these genes
are related to the pathogenesis of A. baumannii. In addition,
transposon screening in other model animals will provide novel
insight into A. baumannii pathogenesis. Knowledge of virulence
factors responsible for A. baumannii pathogenicity will be the
cornerstone for developing novel antibiotics. For example, LPS is
an important virulence factor and LpxC inhibitor, which inhibits
LPS synthesis, completely protects mice from lethal infection
(Lin et al., 2012). These results indicate that blocking LPS
synthesis is a powerful strategy for discovering novel antibiotics.
However, despite recent extensive studies about A. baumannii
pathogenesis, the toxicity and pathogenicity of A. baumannii
remain unclear.
Recent interest about A. baumannii is mostly due to its
seemingly endless capacity to acquire antibiotic resistance. A.
baumannii has almost all bacterial resistance mechanisms. All
class β-lactamases have been detected in A. baumannii and
the frequency of carbapenem-resistant A. baumannii isolates
is very high. Furthermore, almost all A. baumannii contain
aminoglycoside-modifying enzymes and many eﬄux pumps
responsible for resistance to various clinically important
antibiotics have been identified in A. baumannii. Due to these
abilities, available antibiotics to treat A. baumannii infections
are significantly limited. Colistin is used as the antibiotic
treatment of last resort, due to its relatively low resistance rate.
However, emergence of colistin-resistant A. baumannii strains
has increased worldwide with increasing use of colistin. Notably,
some more recent studies have proposed that another polymyxin
antibiotic, polymyxin B, is a potential therapeutic alternative
to colistin (Lenhard et al., 2016a,b; Rao et al., 2016a; Repizo
et al., 2015). Polymyxin B has not been a good antibiotic owing
to dose-dependent nephrotoxicity, but recent reports show that
a novel combination therapy with carbapenems or tigecycline
using minimal concentrations of polymyxin B can be a good
strategy to treat carbapenem-resistant A. baumannii infections.
These results indicate the requirement for extensive studies that
analyze the pharmacodynamics of polymyxin B in combination
therapy.
Various trials to identify a novel alternative to carbapenem
or colistin have been performed. Among them, engineered
endolysins (artilysins) are particularly interesting, despite evident
defects. A lytic enzyme degrading peptidoglycan of bacteria
is a promising novel class of antimicrobial agents due to
its unique mode of action. Similar to β-lactam antibiotics
that are one of the most successful antibiotics, inhibition of
peptidoglycan synthesis is a promising target of antimicrobial
agents. Because lytic enzymes directly degrade peptidoglycans,
but not proteins, the possibility of the emergence of a resistance
mechanism is relatively low. In addition, enzymes with relatively
high molecular weight are not inhibited by eﬄux pumps.
If the short stability of artilysin in serum and high cost
in its production compared with small molecules can be
resolved, the improved artilysin can be a good treatment
option for carbapenem- or colistin-resistant A. baumannii
infections. In conclusion, novel, rationally designed strategies
and screening-based approaches are required to discover new
classes of antibiotics. If we continue to take all efforts at
maintaining the effectiveness of antibiotics and developing novel
antibiotics, effective control of A. baumannii infections can be
successful.
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